On February 6, 2026, Novartis began construction of a new global biomedical research center in San Diego, California, USA.[1] The approximately 466,000 square foot facility is intended to provide state-of-the-art scientific infrastructure and drug discovery capabilities to expand the patient drug pipeline.[1] When commissioned in 2029, it should house about 1,000 Novartis employees.[1] The facility integrates seamlessly with existing global research headquarters in Cambridge, Massachusetts and Basel, Switzerland, enabling integrated drug discovery across regions.[1] It will support end-to-end drug discovery in key disease areas including neuroscience, global health, oncology, age-related diseases and regenerative medicine.[1] It will expand capabilities in advanced technologies such as gene and cell therapy, RNA-based therapies, biologics, targeted protein degradation, and novel drug delivery systems.[1] The construction is part of a $23 billion investment to expand research and development and advanced manufacturing in the US.[1][2] The groundbreaking ceremony was attended by government leaders, community partners and Novartis employees in San Diego.[1]